• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微钙化型浸润性乳腺癌中铸型性钙化的临床病理特征及其预后意义。

Clinicopathological characteristics and prognostic significance of casting-type calcifications in patients with invasive breast cancer presenting with microcalcification.

机构信息

Department of Thyroid and Breast Surgery, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, 322100, Zhejiang, China.

Department of Radiology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, 322100, Zhejiang, China.

出版信息

Sci Rep. 2024 Jun 10;14(1):13351. doi: 10.1038/s41598-024-64353-5.

DOI:10.1038/s41598-024-64353-5
PMID:38858542
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11164990/
Abstract

To explore the clinicopathological characteristics and prognostic significance of casting-type calcification (CC) in patients with breast cancer presenting with microcalcification on mammography. Data on patients with invasive breast cancer who had mammographic calcification was retrospectively analyzed. The chi-square test was utilized to assess the clinicopathological characteristics of two forms of CC-related breast cancer. The examination of prognostic variables was conducted using Kaplan-Meier and Cox regression analyses. A total of 427 eligible patients were included in this study. Chi-square analysis indicated that the presence of CC was associated with estrogen receptor (ER) negativity (P = 0.005), progesterone receptor (PR) negativity (P < 0.001), and epidermal growth factor receptor 2 (HER-2) positivity (P < 0.001); among these, the association was stronger with the CC-predominant type. After a median follow-up of 82 months, those with CC had a worse 5-year recurrence-free survival (RFS) (77.1% vs. 86.9%, p = 0.036; hazard ratio [HR], 1.86; 95% confidence interval [CI] 1.04-3.31) and overall survival (OS) (84.0% vs. 94.4%, p = 0.007; HR, 2.99; 95% CI 1.34-6.65) rates. In COX regression analysis, such differences were still observed in HER-2 positive subgroups (RFS: HR: 2.45, 95% CI 1-5.97, P = 0.049; OS: HR: 4.53, 95% CI 1.17-17.52, P = 0.029). In patients with invasive breast cancer exhibiting calcifications on mammography, the presence of CC, especially the CC-predominant type, is linked to a higher frequency of hormone receptor negativity and HER-2 positivity. The presence of CC is associated with an unfavorable 5-year RFS and OS rates.

摘要

探讨钼靶 X 线表现微钙化的乳腺癌中铸型钙化(CC)的临床病理特征及其预后意义。回顾性分析了伴有乳腺钙化的浸润性乳腺癌患者的资料。采用卡方检验比较两种 CC 相关乳腺癌的临床病理特征。采用 Kaplan-Meier 法和 Cox 回归分析检查预后变量。共纳入 427 例符合条件的患者。卡方分析表明,CC 的存在与雌激素受体(ER)阴性(P=0.005)、孕激素受体(PR)阴性(P<0.001)和表皮生长因子受体 2(HER-2)阳性(P<0.001)相关;其中与 CC 为主型的相关性更强。中位随访 82 个月后,CC 组患者的 5 年无复发生存率(RFS)(77.1%比 86.9%,p=0.036;风险比[HR],1.86;95%置信区间[CI],1.04-3.31)和总生存率(OS)(84.0%比 94.4%,p=0.007;HR,2.99;95%CI,1.34-6.65)更差。COX 回归分析显示,在 HER-2 阳性亚组中仍存在这种差异(RFS:HR:2.45,95%CI 1-5.97,P=0.049;OS:HR:4.53,95%CI 1.17-17.52,P=0.029)。在钼靶 X 线表现为钙化的浸润性乳腺癌患者中,CC 的存在,尤其是 CC 为主型,与激素受体阴性和 HER-2 阳性的发生率更高相关。CC 的存在与 5 年 RFS 和 OS 率较差相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952b/11164990/1475da6ffeb4/41598_2024_64353_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952b/11164990/fc93b7f96bff/41598_2024_64353_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952b/11164990/a477ff8c533c/41598_2024_64353_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952b/11164990/914a160c136b/41598_2024_64353_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952b/11164990/1475da6ffeb4/41598_2024_64353_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952b/11164990/fc93b7f96bff/41598_2024_64353_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952b/11164990/a477ff8c533c/41598_2024_64353_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952b/11164990/914a160c136b/41598_2024_64353_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/952b/11164990/1475da6ffeb4/41598_2024_64353_Fig4_HTML.jpg

相似文献

1
Clinicopathological characteristics and prognostic significance of casting-type calcifications in patients with invasive breast cancer presenting with microcalcification.微钙化型浸润性乳腺癌中铸型性钙化的临床病理特征及其预后意义。
Sci Rep. 2024 Jun 10;14(1):13351. doi: 10.1038/s41598-024-64353-5.
2
Mammographic casting-type calcification is an independent prognostic factor in invasive breast cancer.乳腺 X 线摄影铸造型钙化是浸润性乳腺癌的一个独立预后因素。
Sci Rep. 2019 Jul 22;9(1):10544. doi: 10.1038/s41598-019-47118-3.
3
[Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].[雌激素受体、孕激素受体及人表皮生长因子受体-2在接受乳房切除术的淋巴结阳性乳腺癌患者中的预后价值]
Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):520-5.
4
Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.磷酸化HER2在接受辅助曲妥珠单抗治疗的HER2阳性乳腺癌患者中的预后价值。
Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.
5
HER2-positive breast cancer patients: correlation between mammographic and pathological findings.人表皮生长因子受体2阳性乳腺癌患者:乳腺X线摄影与病理结果的相关性
Radiat Prot Dosimetry. 2014 Nov;162(1-2):125-8. doi: 10.1093/rpd/ncu243. Epub 2014 Jul 25.
6
Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.单一孕激素受体阳性的预后意义:雌激素受体阴性/孕激素受体阳性/人表皮生长因子受体2阴性原发性乳腺癌与三阴性乳腺癌的比较研究
Medicine (Baltimore). 2015 Nov;94(46):e2066. doi: 10.1097/MD.0000000000002066.
7
Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.联合雌激素受体和孕激素受体水平可预测人表皮生长因子受体 2 阳性早期乳腺癌的生存结局。
Clin Breast Cancer. 2022 Feb;22(2):e147-e156. doi: 10.1016/j.clbc.2021.05.012. Epub 2021 Jun 16.
8
[Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].雌激素和孕激素受体阴性且HER-2过表达乳腺癌的临床病理特征及预后因素
Zhonghua Zhong Liu Za Zhi. 2008 Dec;30(12):917-20.
9
The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.乳腺癌患者从原发性病灶到转移病灶的激素受体及人表皮生长因子受体2(Her-2)状态的变化及其临床意义
Tumour Biol. 2016 Jun;37(6):7675-84. doi: 10.1007/s13277-015-4649-7. Epub 2015 Dec 21.
10
Calcification-associated molecular traits and therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.激素受体阳性 HER2 阴性乳腺癌中与钙化相关的分子特征及治疗策略。
Cancer Biol Med. 2024 Apr 9;21(5):400-15. doi: 10.20892/j.issn.2095-3941.2023.0492.

引用本文的文献

1
Extratumoral signs on mammography as a novel prognostic indicator for breast cancer: evidence from malignant nonspiculate and noncalcified masses.乳腺钼靶摄影的瘤外征象作为乳腺癌的一种新的预后指标:来自恶性非毛刺状和非钙化肿块的证据
Am J Transl Res. 2025 Jul 15;17(7):5385-5397. doi: 10.62347/ETGF1320. eCollection 2025.
2
Imaging Biomarkers for HER2-Positive Breast Cancer: Evidence from an Observational Study.HER2阳性乳腺癌的影像生物标志物:一项观察性研究的证据
J Clin Med. 2025 Jul 17;14(14):5056. doi: 10.3390/jcm14145056.

本文引用的文献

1
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update.人表皮生长因子受体 2 检测在乳腺癌中的应用:ASCO-美国病理学家学会指南更新。
J Clin Oncol. 2023 Aug 1;41(22):3867-3872. doi: 10.1200/JCO.22.02864. Epub 2023 Jun 7.
2
[Cancer statistics in China, 2016].《2016年中国癌症统计数据》
Zhonghua Zhong Liu Za Zhi. 2023 Mar 23;45(3):212-220. doi: 10.3760/cma.j.cn112152-20220922-00647.
3
Imaging biomarkers of breast cancers originating from the major lactiferous ducts: Ductal adenocarcinoma of the breast, DAB.
源于主要输乳管的乳腺癌的影像学标志物:乳腺导管腺癌,DAB。
Eur J Radiol. 2022 Sep;154:110394. doi: 10.1016/j.ejrad.2022.110394. Epub 2022 Jun 4.
4
Breast cancers originating from the major lactiferous ducts and the process of neoductgenesis: Ductal Adenocarcinoma of the Breast, DAB.起源于主要输乳管的乳腺癌及新导管生成过程:乳腺导管腺癌,DAB
Eur J Radiol. 2022 Aug;153:110363. doi: 10.1016/j.ejrad.2022.110363. Epub 2022 May 18.
5
Breast cancers originating from the terminal ductal lobular units: In situ and invasive acinar adenocarcinoma of the breast, AAB.来源于终末导管小叶单位的乳腺癌:乳腺原位和浸润性腺样囊性癌,AAB。
Eur J Radiol. 2022 Jul;152:110323. doi: 10.1016/j.ejrad.2022.110323. Epub 2022 May 10.
6
A new approach to breast cancer terminology based on the anatomic site of tumour origin: The importance of radiologic imaging biomarkers.一种基于肿瘤起源部位的乳腺癌术语新方法:放射影像学生物标志物的重要性。
Eur J Radiol. 2022 Apr;149:110189. doi: 10.1016/j.ejrad.2022.110189. Epub 2022 Feb 9.
7
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
8
Breast cancer stem cells: A review of their characteristics and the agents that affect them.乳腺癌干细胞:其特征及影响它们的因子综述
Mol Carcinog. 2021 Feb;60(2):73-100. doi: 10.1002/mc.23277. Epub 2021 Jan 11.
9
What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer?雌激素受体状态对 HER2 阳性早期乳腺癌的预后和治疗的真正影响是什么?
Clin Cancer Res. 2020 Jun 15;26(12):2783-2788. doi: 10.1158/1078-0432.CCR-19-2612. Epub 2020 Feb 11.
10
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.乳腺癌中雌激素和孕激素受体检测:ASCO/CAP 指南更新。
J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309. Epub 2020 Jan 13.